Investigation of RNA interference to suppress expression of full-length and fragment human huntingtin.

Mark McIntosh,'s picture
PubMed URL:
Borchelt DR
Author List: 
Gary DS
Davidson A
Milhavet O
Slunt H
Borchelt DR
Neuromolecular Med
PubMed ID: 
The use of RNA interference (RNAi) to suppress the expression of genes has drastically improved the ability to examine gene function and is now being considered as a therapeutic approach for many diseases including genetic forms of neurodegenerative disease. Recently, research has focused on RNAi for the treatment of Huntington's and other polyglutamine diseases. In this work we explored the efficacy and specificity of short hairpin RNAs to target human huntingtin mRNA. We found two sequences that are specific for, and efficiently suppress human huntingtin mRNA. Mouse cell lines that stably harbored human short hairpin RNA constructs specifically inhibited the expression of human huntingtin supplied by transfected expression plasmids. However, these same constructs were unable to stably suppress endogenous human huntingtin when stably transfected into human 293 cells, despite effectively knocking down expression of huntingtin in transient transfection. These results demonstrate the efficacy and specificity of RNAi as a tool to target human huntingtin in RNAi-based therapies but point toward potential problems, possibly cell-type specific, regarding stable suppression of human huntingtin.
Published Date: 
January, 2007

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.

Appointments & Referrals



Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.


Resource Finder


A free resource that provides access to information and support for individuals and families living with developmental disabilities.